This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.
Study Type
OBSERVATIONAL
Enrollment
1,000
Observational study of this study, no interventions involved
Anhui Cancer Hospital
Hefei, Anhui, China
Maanshan People's Hospital
Maanshan, Anhui, China
Hainan General Hospital
Haikou, Hainan, China
Percentage and severity of Participants With Adverse Events (AEs)
percentage and CTC AE(v5.0) of AEs
Time frame: 28 days after the end of the last chemotherapy cycle
Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR is defined as the rate of CR or PR, as determined by IRC using RECIST v1.1 criteria.
Time frame: From signing informed consent，assessed up to end of study (up to approximately 24months)
evaluate patients' quality of life by the European Cancer Research and Treatment Tissue Cancer Quality Core Questionnaire EORTCQLQ-C30
EORTC QLQC30 scale was used to score the quality of life before treatment, at each chemotherapy cycle, and at the end of treatment.
Time frame: From signing informed consent，assessed up to end of study (up to approximately 24months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Tumor Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, Inner Mongolia, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China
...and 4 more locations